Heartmate XVE(R) destination therapy for end-stage heart failure in a patient with human immunodeficiency virus

Abstract

Cardiac dysfunction is a known predictor of survival in patients with acquired immunodeficiency syndrome. In this report, we describe a human immunodeficiency virus (HIV)-infected patient with worsening heart failure who was managed successfully for 16 months with placement of a left ventricular assist device.

Heart Failure in Patients With Human Immunodeficiency Virus Infection

“…87, 88 Both patients did well and did not suffer complications much different from those by non-HIV-1 infected left ventricular assist device recipients. A subsequent case demonstrated no major infectious related complications 89 and no significant increased risk of allosensitization.…”

Human immunodeficiency virus infection and left ventricular assist devices: A case series

“…14 Two patients with known HIV implanted with an LVAD have been reported. 5,6 Both patients with known HIV received a HeartMate XVE pulsatile-flow LVAD and lived for 16 months before they died. One patient died of renal failure 5 and the other died of LVAD malfunction.…”

“…6 One patient had no infectious complications, 6 whereas the other had a Staphylococcus aureus driveline infection requiring debridement and an Acinetobacter pneumonia. 5 Neither of these infectious complications can be attributed to HIV.…”

Left Ventricular Assist Device: What the Internist Needs to Know. A Review of the Literature

“…Intra-cardiac shunts are typically closed at the time of VAD implantation. Pre-existing mechanical or biological mitral or aortic prosthetic valves usually do not cause complications during LVAD implantation [34,35].…”